Sergei Left a comment on LinkedIn

[biopearl123]

Sergei seems happy that his creation has found deserved recognition. Wish he would come back home to Geron and bring MAIA with him.

[LWS]

I am sure Sergei is very happy. MAIA is getting a very strong tail-wind from Imetelstat's very positive ODAC recommendation.

Some have previously suggested that there are overlapping patents. It would make both good business sense and good medical sense for both companies (Geron and MAIA) to find a convenient way to work together on new cancer treatments and potential cures.
==================

MAIA Biotechnology, Inc. (MAIA)

2.1366 +0.1966
(+10.1340%)

As of 1:00 PM EDT. Market Open.

[LWS]

Some History for those that are new to this board
========================

Posted Dec. 27, 2023

Telomerase Inhibitors for Potentially 90% of all Cancers

MD Anderson and the University of Texas medical unit are already partners. They are building the ulitmate cancer research and treatment center in Austin Texas. Both are well aware of Imetelstat and THIO. I suspect they are involved in intellectual property discussions, including overlapping patents.

Imetelstat's NDA approval (blood cancers) will also be a major victory for MAIA (solid cancers with delivery systems) for their proof of concept. It makes sense for the two companies (Geron & MAIA) to find a way to collaborate. We are talking about partial remissions, complete remissions, and, hopefully, some cures. This is just the beginning.
=================================
History Lesson: Imetelstat (IMET has come a long way since ET). Dr. Sergei Gryaznov (Dr. G, now at MAIA), formerly Geron's (NASDAQ: GERN) Chief Scientist in Nucleic Acid Chemistry, is the named inventor of GRN163L, also known as Imetelstat

[LWS]

The most obvious connection between Geron and MAIA is Sergei. I suspect when Imetelstat finally gets FDA approval (blood cancers), that will be very beneficial to THIO --- solid cancer treatment and perhaps accelerated approvals for MAIA/THIO. Other connections are patents, MD Anderson and the University of Texas. The world of cancer treatments will change significantly with Imetelstat's approval.

Geron's PPS and MAIA's PPS are tracking each other.